The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

November 17, 2017 • By Deena Beasley

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers.

You Might Also Like
  • Trump Administration Proposes Stricter Obamacare Rules
  • U.S. Government Proposes Rule Overhauling Drug Industry Rebate System
  • U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans

To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said it was considering allowing drug coverage plans to require beneficiaries to obtain prescriptions for opioids only from selected prescribers or pharmacies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

CMS, part of the U.S. Department of Health and Human Services, oversees healthcare and drug benefits under the government-paid health plan for older and disabled people, which includes coverage plans managed by private insurers.

CMS said it is requesting information on applying discounts drug companies negotiate with health plans to prices beneficiaries pay at the pharmacy counter. Drugmakers have argued that consumers with high deductibles or other coverage limitations are not getting the benefit of such contracted discounts.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The proposal signals “that CMS is starting down the road of potentially disrupting the prescription drug rebate and distribution system,” Evercore ISI analyst Michael Newshel said in a research note.

The drug industry has been on edge for two years about the potential for more government pressure on pricing after sharp increases in the costs of some life-saving drugs drew scrutiny in the press and among lawmakers.

Newshel said the CMS change could lower the out-of-pocket price paid by consumers for brand-name drugs, while also potentially lowering the revenue and rebate dollars that now flow to drug distributors and pharmacy benefit managers (PBMs), particularly if such a move to transparency were adopted more broadly beyond Medicare.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Health insurers often contract with PBMs like Express Scripts Holding Co to manage plans for prescription drugs, which are distributed by wholesalers, such as AmeriSource Bergen Corp and McKesson Corp.

CMS said it is also considering a change in treatment of biosimilar drugs, which are copies of expensive biotechnology drugs that have lost patent protection. To encourage the use of lower-cost alternatives, CMS said it may cover biosimilars like other generic drugs when determining how much certain beneficiaries pay for drugs out of pocket.

The agency may also allow midyear changes to prescription drug formularies when a new, lower-cost generic becomes available and may revise pharmacy participation rules to promote greater participation of local pharmacies.

President Trump has in the past championed other tactics for reducing prescription prices, including allowing Medicare to directly negotiate with drug companies or import medicines from other countries. But those options were not mentioned in the proposed rule changes.

If finalized, the changes would take effect in contract year 2019.

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates Tagged With: drug costs, Medicare, Opioids, prescription drug costs, Trump administration

You Might Also Like:
  • Trump Administration Proposes Stricter Obamacare Rules
  • U.S. Government Proposes Rule Overhauling Drug Industry Rebate System
  • U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans
  • Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.